ORMP — ORAMED PHARMACEUTICALS INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1176309 ·
Last close
$4.04
Market Cap
$165.34M
52W High
$5.01
52W Low
$3.15
ADV30
179,707
Next earnings
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 0 -3,659,000 38,310,000 268,847,000 13,202,000 30,571,000
Dec 2025 0 0 -5,672,000 10,009,000 230,864,000 45,947,000 31,120,000
Sep 2025 0 0 -2,427,000 48,395,000 220,493,000 52,179,000 18,163,000
Jun 2025 0 0 -2,489,000 13,288,000 161,684,000 15,797,000 8,101,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,145,000
Investing CF
$5,443,000
Financing CF
$-4,741,000
CapEx
$-2,146,000
Dividends Paid
Buybacks
$-6,854,000
EPS Diluted TTM
$0.77
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-123,436,000
Inventory
Receivables
$4,636,000
ST Investments
$79,947,000
EBIT TTM
$77,882,000
Pretax Income TTM
$75,324,000
Interest Exp TTM
$2,558,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-14,126,000
Free Cash Flow
$250,625
Enterprise Value
$98,216,064
Total Cash
$65,840,000
Total Debt
$761,000
Shares Out
40,926,081
Trailing EPS
$2.60
Book Value
$5.09
ROE
58.2%
ROA
-4.3%
Div Yield
6.27%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,000,000 -15,088,000 64,050,000 230,864,000 31,120,000 -9,145,000
Dec 2024 0 -12,781,000 -19,060,000 155,278,000 9,931,000 -8,412,000
Dec 2023 1,340,000 -15,769,000 5,525,000 220,551,000 57,658,000 -10,295,000
Dec 2022 2,703,000 -40,598,000 -36,561,000 161,642,000 10,486,000 -27,918,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.08

Peers — same industry

TickerNameMarket CapLastDaily %
PRQR ProQR Therapeutics N.V. $165.42M $1.57
SPRO Spero Therapeutics, Inc. $165.60M $2.86
ENLV Enlivex Ltd. $164.88M $0.68
OKUR OnKure Therapeutics, Inc. $166.43M $4.12
HRTX HERON THERAPEUTICS, INC. /DE/ $167.19M $0.88

News headlines (Yahoo Finance, 1h cache)

Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
2026-05-13 12:05 · Yahoo
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
2026-04-14 18:06 · Yahoo
Oramed: Q4 Earnings Snapshot
2026-03-26 21:50 · Yahoo
Lifeward Successfully Closes on Strategic Partnership with Oramed
2026-03-25 20:10 · Yahoo
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
2026-03-13 12:00 · Yahoo
ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value
2026-02-26 16:10 · Yahoo
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
2026-02-03 15:20 · Yahoo
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
2026-02-03 15:06 · Yahoo
3 Promising Penny Stocks With Market Caps Under $200M
2026-01-14 12:05 · Yahoo
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
2026-01-13 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.